|
References
1. Gruber KA, Whitaker JM, Bucklew VM. Endogenous digitalis-like substances in plasma of volume expanded dogs. Nature 1980;287;743-745.
2. Balzan S, Clerico A, Del Chicca MG, et al. Digoxin-like immunoreactivity in normal human plasma and urine as detected by a solid phase radioimmunoassay. Clin Chem 1984:30;450-451.
3. Valdes R, Graves SW. Protein binding of endogenous digoxin-like immunoreactive factors in human serum and its variation with clinical conditions. J Endocrin Metabolism 1985;60:1257-1260.
4. Krivoy N, Lalkin A, Jakobe P. Digoxin-like immunoreactivity detected in cerebrospinal fluid of humans in fever. Clin Chem 1990:36; 703-704.
5. Jacobi P, Krivoy N, Schwarz K, Aryeh HB, Laufer D. Digoxin-like immunoreactivity in plasma and saliva of pregnant women. Clin Chem 1991:37; 135-136.
6. Graves SW, Brown BA, Valdes R. Digoxin-like immunoreactive substances in a patient with renal impairment. Ann Intern Med 1983: 99;604-608.
7. Soldin SJ. Digoxin issues and controversies. Clin Chem 1986;32:5-12.
8. Nanja AA, Greenway DC. Falsely raised plasma digoxin concentrations in liver disease. British Med J 1985:290; 432-435.
9. Cloix JF. Endogenous digitalis-like compounds. Hypertension 1987;10(Supply); 67-70.
10. Valdes R. Endogenous digoxin-like immunoreactive factors; impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31:1525-1532.
11. Miller JJ, Straub RW, Valdes R. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180. Ther Drug Monit 1996;18;65-72.
12. Dasgupta A, Trejo O. Suppression of total digoxin concentrations by digoxin-like immunoreactive substances in the MEIA digoxin assay: elimination of negative interference by monitoring free digoxin concentrations. Am J Clin Pathol 1999;111:406-410.
13. Dasgupta A, Schammel D, Limmany A, Datta P. Estimating concentrations of total digoxin and digoxin-like immunoreactive substances in volume expanded patients treated with digoxin. Ther Drug Monit 1996;18:34-39.
14. Ocal IT, Green TR. Serum digoxin in the presence of digibind: determination of digoxin by the Abbott AxSYM and Baxter Stratus II immunoassays by direct analysis without pretreatment of serum samples. Clin Chem 1998;44:1947-1950.
15. Rainey P. Digibind and free digoxin. Clin Chem 1999;45:719-720.
16. Steimer W, Muller C, Eber B. Digoxin assays: frequent, substantial and potentially dangerous interference by spironolactone, canrenone and other steroids. Clin Chem 2002;48:507-516.
17. Dasgupta A, Saffer H, Wells A, DattaP. Bidirectional (positive/negative) interference of spironolactone, canrenone and potassium canrenoate on serum digoxin measurement: elimination of interference by measuring free digoxin or using a chemiluminescent assay. J Clin Lab Anal 2002; 16: 172-177.
18. Howard G, Barclay M, Florkowski C, Moore G, Roche A. Lack of clinically significant interference by spironolactone with the AxSYM digoxin II assay. Ther Drug Monit 2003;25:112-113.
19. Hermida J, Tutor JC. How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine 10, 11-epoxide in serum samples? Ther Drug Monit 2003;25:384-388.
20. Matos ME, Burns MM, Shannon MW. False positive tricyclic antidepressant drug screen result leading to the diagnosis of carbamazepine intoxication. Pediatrics 2000;105: E661-E663.
21. Chattergoon DS, Verjee Z, Anderson M, et al. Carbamazepine interferes with an immunoassay for tricyclic antidepressant in plasma. J Toxicol Clin Toxicol 1998;36:109-113.
22. Hackett LP, Dusci LJ, Ilett KF. A comparison of high performance liquid chromatography and fluorescence polarization immunoassay for therapeutic drug monitoring of tricyclic antidepressants. Ther Drug Monit 1998;20:30-34.
23. Roberts W, De B, Coleman J, Annesley T. Falsely increased immunoassay measurement of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin. Clin Chem 1999;45:829-837.
|